Author

M. Ruyken

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 5 Organism:human· 4 Assay:proteomics· 3 Organism:E. coli· 2 Approach:benchmark study· 1 Research Focus:benchmarking· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

B. W. Bardoel· 4 shared S. H. M. Rooijakkers· 4 shared C. J. C. de Haas· 3 shared D. J. Doorduijn· 3 shared D. A. C. Heesterbeek· 2 shared J. van Strijp· 2 shared K. P. M. van Kessel· 2 shared P. Gros· 2 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

B. W. Bardoel

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies

E. M. Struijf, K. I. De la O Becerra, M. Ruyken, F. van Oosterom, D. Y. Siere, D. A. C. Heesterbeek, E. Dolk, R. Heukers, B. W. Bardoel, P. Gros, S. H. M. Rooijakkers

This study identifies and characterizes two high-affinity anti-C5 nanobodies that inhibit C5 cleavage and recognize distinct epitopes, including a variant not targeted by Eculizumab.

bioRxiv · Feb 22, 2023Immunology

Soluble MAC is primarily released from MAC-resistant bacteria that potently convert complement component C5

D. J. Doorduijn, M. V. Lukassen, M. F. L. van 't Wout, V. Franc, M. Ruyken, B. W. Bardoel, A. J. R. Heck, S. H. M. Rooijakkers

The paper investigates how soluble MAC (sMAC) is formed during bacterial infections, finding that MAC-resistant bacteria convert C5 into C5b more efficiently and release sMAC, which can lyse bystander erythrocytes.

bioRxiv · Dec 15, 2021Microbiology

Polymerization of C9 enhances bacterial cell envelope damage and killing by membrane attack complex pores

D. J. Doorduijn, D. A. C. Heesterbeek, M. Ruyken, C. J. C. de Haas, D. A. C. Stapels, P. C. Aerts, S. H. M. Rooijakkers, B. W. Bardoel

This study shows that C9 polymerization enhances MAC pore-mediated bacterial killing and is impaired in complement-resistant strains.

bioRxiv · May 12, 2021Microbiology

C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases

S. A. Zwarthoff, K. Widmer, A. Kuipers, J. Strasser, M. Ruyken, P. Aerts, C. J. C. de Haas, D. Ugurlar, G. Vidarsson, J. van Strijp, P. Gros, P. Parren, K. P. M. van Kessel, J. Preiner, F. J. Beurskens, , S. H. M. Rooijakkers

This study shows that C1r2s2 proteases stabilize C1q binding to surface-bound IgG, with subclass-specific effects and improved phagocytosis with hexamer-enhanced IgGs.

bioRxiv · Feb 8, 2021Immunology

Bacterial immune evasion proteins: The therapeutic potential of CHIPS

A. Tromp, Y. Zhao, I. Jongerius, E. C. Heezius, P. Abrial, M. Ruyken, J. van Strijp, C. J. C. de Haas, A. Spaan, K. P. M. van Kessel, T. Henry, P.-J. A. Haas

This study evaluates CHIPS as a therapeutic agent for inflammation, showing promise in mice but safety concerns in humans due to pre-existing antibodies.

bioRxiv · Feb 25, 2020 · PreprintMicrobiology

Bacterial killing by complement requires direct anchoring of Membrane Attack Complex precursor C5b-7

D. J. Doorduijn, B. W. Bardoel, D. A. Heesterbeek, M. Ruyken, G. Benn, E. S. Parsons, B. Hoogenboom, S. H. Rooijakkers

This study shows that direct anchoring of C5b-7 is essential for MAC pore formation and bacterial killing, and bacteria can evade this by interfering with anchoring.

bioRxiv · Dec 17, 2019Immunology